Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Children's Oncology Group
- Study ID
- NCT00008424
- Phase
- PHASE1
- Status
- Completed
Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children with refractory or advanced solid tumors who are receiving anticonvulsants.
Key Dates
- Start date
- Oct 31, 2000
- Status verified
- May 2014
- Primary completion
- Sep 30, 2005
- Completion
- Sep 30, 2006
Study Design
- Enrollment
- 7 participants (actual)
- Primary purpose
- TREATMENT
Primary Outcome Measure
Maximum tolerable dose (MTD) of irinotecan
Locations (45)
Find similar trials in Little Rock, AR
By research site
University of Arkansas for Medical Sciences· Little Rock, ARCancer Center and Beckman Research Institute, City of Hope· Duarte, CAUniversity of California San Diego Cancer Center· La Jolla, CAChildren's Hospital Los Angeles· Los Angeles, CAJonsson Comprehensive Cancer Center, UCLA· Los Angeles, CAChildren's Hospital of Orange County· Orange, CA
Related Studies
- Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsRecruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina